2 completed, 1 active not recruiting. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow CS-1003: new trials by email Literature Review of CS-1003 trials Research Report on CS-1003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | CStone Pharmaceuticals | 534 | 2019-12-13 | 2026-07-30 |
| A Study of CS1003 in Subjects With Advanced Solid Tumors CS1003, Regorafenib - Advanced Cancer | Phase 1 | Completed | CStone Pharmaceuticals | 108 | 2018-05-09 | 2022-02-18 |
| A Study of CS1002 in Subjects with Advanced Solid Tumors CS1002, CS1003 - Solid Tumor, Adult | Phase 1 | Completed | CStone Pharmaceuticals | 91 | 2018-04-26 | 2024-09-19 |
Australia (2) · China (1) · Hong Kong (1) · Italy (1) · Poland (1) · Spain (1) · Taiwan (1) · United States (1)
Wanmei Wang (1)